Featured Opinions
Deirdre Coleman speaks to Pelin Icil, Marketing Manager, Bayer Healthcare (Women’s Health) about what women want and expect from pharma companies and Bayer’s newly launched Women’s Health TV.
What Patient Centric Leadership Looks Like
by Paul Simms
Paul Simms talks to Gitte P. Aabo, President & CEO of LEO Pharma, about patient centricity, new solutions within dermatology, partnerships and what the future holds.
by Kevin Dolgin
Hello all.It's been a few months since my last column, but I have a great excuse... I've been really, really busy.Anyway, the kind and insistent people at eyeforpharma have asked me if I could pick up where I left off and I'm quite happy to do so.
We are all patient-centric now — aren't we?
With patient centricity firmly on the agenda, what is true patient centricity and how can we translate the intent to align more with action? I interviewed executives at Novo Nordisk and Sanofi to highlight the three key things to consider when seeking to be patient centric.
by Marc Yates
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
Is Your Commercial Operation Ready for Healthcare 2.0?
The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Rethinking Pharma Part 1: How Precision Medicine is Changing the Game
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.
Putting the ‘me’ into medicine
This is the first of a new monthly column addressing patient centricity and the transition to consumerized medicine and points to lessons that can be learned from the entertainment, luxury goods and retail industries.
Exploring MINT: Part 4 - Turkey
by Marc Yates
In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Turkey.
Implementing disruptive selling skills
by Ifti Ahmed
A definition of madness is doing the same thing and expecting different results.
Do You Make These Strategic Planning Mistakes?
There is an epidemic of sticking roughly to the previous year's plan and budget. This may be useful if that approach is getting you to be the top brand, but if your results are not radically improving you need to examine both your strategy and budget allocation carefully.
In Conversation with Paul Simms: Rice Powell, CEO, Fresenius Medical Care
by Paul Simms
Rice Powell, Chairman of the Board and CEO for Fresenius Medical Care, speaks to Paul Simms, eyeforpharma Chairman. Fresenius Medical Care is a company well-known for being the first to successfully pioneer a vertically-intergrated, service-oriented model within healthcare.
Value innovation realized through services
by Jeff Elton
As we enter into the "Value Era", innovating and delivering value is about understanding critical connections, gaps, and potential solutions or alternatives to each. Jeff Elton discusses the exciting emergence of a truly global health services solutions market.
Exploring MINT: Part 3 - Nigeria
by Marc Yates
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.
Exchanges: Shaping the Consumers of the Future
Although the exchanges have the potential to expand the market for some therapeutic areas, the way in which they are designed will likely have an impact on consumer purchasing behavior. Manufacturers need to understand how consumers are responding and what these changes mean for their business.
Time for change in segmentation and targeting
by David Laws
Segmentation and targeting remain critical ingredients for sales and marketing success, despite significant changes in the healthcare environment, but little has substantially changed in the way big pharma segments its customer base.
Great Expectations: How to Attract, Retain and Manage the Female Millennial
Female millennials matter because they are more highly educated than previous generations (according to research) and are set to represent 25% of the global workforce by 2020. However, meeting their employer expectations is a challenge that requires deep insight into their behaviors and motivations.
Exploring MINT: Part 2 - Indonesia
by Marc Yates
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with a focus on the impact of its planned roll-out of a universal healthcare system.
Will Biosimilars Meet the Market Similar Test?
Biosimilars face a dual challenge of competing with the original product’s clinical and marketing profile, i.e. are they both biosimilar and market similar. In this competitive environment, whatever approach biosimilar manufacturers select must demonstrate how their product adds value.
What does ‘value’ mean in Healthcare?
by Jeff Elton
Jeff Elton, managing director of Accenture Life Sciences, discusses a new era of value-enhancing innovation that will directly affect the delivery of value to patients and providers
Exploring MINT: Part 1 - Mexico
by Marc Yates
In the first of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Mexico.
Building Trust through Collaboration: An Interview with Jane Griffiths
Following her keynote presentation at eyeforpharma Barcelona 2014, Jane Griffiths, Janssen Company Group Chairman, EMEA, was interviewed by Paul Simms, eyeforpharma Chairman, and discusses how the pharmaceutical industry needs to build trust through collaboration.
“After all, the industry is here to make a profit”
by David Laws
This common refrain is often used to justify pharma pricing but it is not doing pharma any favors when it comes to public opinion.
The Untapped Potential of ASEAN: The key growth factors
by Marc Yates
In part 2 of the ASEAN series, Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
No More Lip Service – Just do it
Pharma is in deep deep trouble. It is being out-innovated and its reaction is to restructure, downsize or engage in mergers and acquisitions to fill pipeline gaps. It's time for reinvention according to Dr Andree Bates.